Intramyocardial Adenovirus-Mediated VEGF-DΔNΔC Gene Transfer in Patients with No-Option Coronary Artery Disease: Interim Safety Analysis of the Kuopio Angiogenesis Trial 301

Intramyocardial Adenovirus-Mediated VEGF-DΔNΔC Gene Transfer in Patients with No-Option Coronary Artery Disease: Interim Safety Analysis

VEGF- mediated gene therapy is a potential new treatment for patients with advanced cardiovascular diseases. However, previous clinical trials have not been able to convincingly demonstrate the efficiency of VEGF gene therapy in humans. Low gene transfer efficiency and insufficient gene expression time could be major contributing factors. To improve these shortcomings we have started a new intramyocardial gene therapy trial with adenoviral (Adv)VEGF-DΔNΔC.